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Interbase‑FRET binding assay 
for pre‑microRNAs
Mattias Bood1,3, Anna Wypijewska del Nogal2, Jesper R. Nilsson2, Fredrik Edfeldt4, 
Anders Dahlén5, Malin Lemurell3, L. Marcus Wilhelmsson2 & Morten Grøtli1*
The aberrant expression of microRNAs (miRs) has been linked to several human diseases. A promising 
approach for targeting these anomalies is the use of small‑molecule inhibitors of miR biogenesis. 
These inhibitors have the potential to (i) dissect miR mechanisms of action, (ii) discover new drug 
targets, and (iii) function as new therapeutic agents. Here, we designed Förster resonance energy 
transfer (FRET)‑labeled oligoribonucleotides of the precursor of the oncogenic miR‑21 (pre‑miR‑21) 
and used them together with a set of aminoglycosides to develop an interbase‑FRET assay to detect 
ligand binding to pre‑miRs. Our interbase‑FRET assay accurately reports structural changes of the 
RNA oligonucleotide induced by ligand binding. We demonstrate its application in a rapid, qualitative 
drug candidate screen by assessing the relative binding affinity between 12 aminoglycoside antibiotics 
and pre‑miR‑21. Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) were 
used to validate our new FRET method, and the accuracy of our FRET assay was shown to be similar to 
the established techniques. With its advantages over SPR and ITC owing to its high sensitivity, small 
sample size, straightforward technique and the possibility for high‑throughput expansion, we envision 
that our solution‑based method can be applied in pre‑miRNA–target binding studies.
MicroRNAs (miRs) are short (typically 22 nt) single-stranded RNAs that have important cellular functions 
and are dysregulated in a variety of human diseases, including cancers, viral infections, cardiovascular dis-
ease, and inflammatory  diseases1. Currently, 1,917 human miR precursor genes, which are processed into 2,675 
mature miRs, have been annotated in the miRBase  database2 and are thought to regulate one-third of the human 
 proteome3. Genes encoding miRs are transcribed as long RNA precursors, which are processed by the Drosha 
nuclear microprocessor complex to yield approximately 70 nt hairpin precursor miRs (pre-miRs)4. Pre-miRs 
are then transported to the cytoplasm for further processing by RNase III Dicer to form a double-stranded RNA 
(dsRNA) molecule. One of its strands, the mature miR, is loaded into the RNA-induced silencing complex, which 
binds the complementary mRNA target through Watson–Crick base pairing and mediates gene silencing. Stud-
ies have demonstrated that numerous miRs act as tumor suppressors or oncogenes (also termed ‘onco-miRs’)5. 
Only a few onco-miRs have been well characterized so far, one of these being miR-216. The identification of 
small molecules that bind to onco-miR precursors (such as the pre-miR-21 presented herein) could be a viable 
approach to inhibit the biogenesis of miRs that are involved in cancer development and could lead to mechanisti-
cally novel cancer  therapies7. Furthermore, miRs have now been thoroughly validated as a therapeutic  target8.
The most commonly employed method to target disease-associated miRs is based on the use of antisense 
 technologies9,10. However, this approach primarily relies on modified oligonucleotide structures; these struc-
tures suffer from poor cell permeability and cellular distribution due to their intrinsic anionic  character11. In 
contrast, small molecules offer the advantage of having good absorption, distribution, and oral bioavailability. 
Furthermore, rather than using sequence complementarity for binding, small molecules have the potential to 
recognize and bind to pre-miRs through RNA secondary or tertiary structural motifs, such as bulges, internal 
loops, hairpin loops, junctions, pseudoknots, or higher-order structural  elements12.
Several cellular and non-cellular reporter-based assays have previously been applied to identify small-mol-
ecule inhibitors of pre-miR-mediated gene  silencing7. Unfortunately, these assays all have their limitations. In 
general, small-molecule  microarrays13,14, molecular  beacons15–17, fluorescence  polarization18,19, and catalytic 
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enzyme-linked click chemistry  assays20 all utilize reporter probes that are either large or amphiphilic and poten-
tially interfere with the assay and/or are distant from the binding site of interest. Small-molecule binding assays, 
such as fluorescence indicator  displacement21 require either selectively binding fluorophores or the displacement 
of more promiscuous probes, such as ethidium bromide, which can cause false negatives if the mode of binding 
differs. The hits from such assays have typically been verified by examining the maturation level of the pre-miR 
after adding the Dicer  enzyme16 and in several cases they have been furthered characterized using additional 
biophysical techniques such as isothermal titration calorimetry (ITC)13, differential scanning calorimetry (DSC)14 
or surface plasmon resonance (SPR)22.
Biophysical techniques such as ITC and SPR are well suited for resolving direct pre-miR engagement and 
were employed as benchmark methods in the current study. A significant advantage of ITC is that it can be read-
ily applied to almost any RNA–ligand complex without the need to label both molecules. Additionally, it can 
be performed under a broad range of pH values, temperatures, and ionic concentrations. The major drawbacks 
of ITC, namely, the limited throughput and a significant sample size, is partly mitigated by SPR. However, SPR 
also has disadvantages, as it cannot easily discriminate between specific and non-specific interactions with the 
sensor surface.
Förster resonance energy transfer (FRET) is a non-radiative process in which energy is transferred between 
donor and acceptor  chromophores23. The efficiency of this process is highly dependent on both distance and 
orientation between the chromophores. Consequently, information about the relative position of different donor- 
and acceptor-labelled biomolecules and thereby the structure of the biomolecule can be  obtained24. FRET has 
been used in the molecular beacon (MB) assay format to measure the inhibition of Dicer-mediated pre-miR 
hairpin  cleavage15–17. The compounds tested in previous studies have typically been ranked relative to each 
other using the fluorescence increase resulting from the Dicer RNase activity. A potential drawback of MB 
pre-miR-assays is that the large amphiphilic FRET probes are attached to the ends of the oligoribonucleotide; 
this can significantly impact the results because Dicer recognizes both the 3′- and 5′-end of the pre-miR15,25. 
Unfortunately, no counter-screen has been performed to determine the detailed binding parameters; thus, the 
developed MB assay could not be benchmarked against established techniques. While a FRET MB assay can 
identify hits for Dicer inhibition, it cannot resolve subtle changes in ligand binding, such as local conformational 
changes in the RNA  structure26.
In an attempt to combine a high-information screening technique with a potential high-throughput screen-
ing method, we aimed to mitigate the shortcomings of MB assays and direct pre-miR engagement assays such 
as SPR. FRET between conformationally restricted, non-perturbing, fluorescent nucleobase analogs (FBAs), 
called interbase FRET, can be utilized to measure distance and orientation between the involved donor and 
acceptor  molecules27. This offers the possibility not only to measure Dicer inhibition more accurately from a 
ligand-binding event due to their non-perturbing nature but could also, if positioned wisely, be used to identify 
site-selective ligand binders. We have previously demonstrated that the emissive cytosine analogue 3-(β-d-
ribofuranosyl)-3H-benzo[b]pyrimido[4,5-e][1,4]oxazin-2(10H)-one  (tCO)39 (Fig. 1d) can be used together with 
the non-emissive 3-(β-d-ribofuranosyl)-7-nitro-3H-pyrimido[5,4-b][1,4]benzothiazin-2(10H)-one  (tCnitro)28 
(Fig. 1d), to create an interbase-FRET pair. This combination of cytosine analogues have been used to monitor 
the transition from A- to Z-form RNA with no significant perturbation of the natural RNA  structure28.
Previous work has demonstrated that  aminoglycosides29 have a general affinity towards  RNA30–33, including 
pre-miR-2113,22,34–38. However, the specificity of these binding events has yet to be fully  elucidated38. Aminogly-
cosides have also been used to construct bifunctional aminoglycoside conjugates that consist of a pre-miRNA 
binding unit that is connected by a linker to a Dicer inhibiting unit that binds pre-miR-21 and regulates miR-21 
 maturation19. From the typical molecular structures of aminoglycosides (Figure S2), they are expected to be 
non-fluorescent and not to absorb light in the spectral region relevant for  tCO–tCnitro FRET (i.e., above 350 nm, 
Figure S1)28,39. Hence, aminoglycosides will not interfere with the energy transfer process of our FRET pair, and 
we therefore decided to employ them as test compounds in this work to validate our pre-miR-21 FRET-based 
ligand-binding assay, which utilizes a  tCO–tCnitro RNA FRET  pair28.
Small molecules contained in screening libraries can themselves be fluorescent or act as a quencher, leading 
to potential false results through interference with the  tCO–tCnitro RNA FRET pair. However, this potential prob-
lem can be reduced by eliminating library compounds with larger conjugated aromatic systems. Furthermore, 
counter assays can be utilized to identify compounds that can potentially interfere with the detection method.
Results and discussion
FRET‑labelled oligoribonucleotide design. Mature miRs do not contain secondary structural elements 
that allow specific and high-affinity binding by small molecules. Consequently, miR-regulating strategies utiliz-
ing small molecules are often based on pri- or pre-miR biogenesis. The pre-miRs are approximately 70 nt-long 
hairpins containing discrete secondary and tertiary structures that are susceptive to specific binding by drug-
like molecules. An examination of the predicted secondary structure of the full-length pre-miR-21 hairpin (1, 
Table 1, Fig. 1a)40 and the available solution-NMR structure of the pre-miR-21 hairpin  segment34 revealed that 
the majority of the secondary structures to which a ligand could potentially bind (mismatch bulges and a hair-
pin loop) were located in proximity to the hairpin loop and the functional Dicer processing site (Fig. 1a). From 
a chemical synthesis point of view, long, modified RNA sequences are challenging to prepare, which led us to 
truncate the full-length pre-miR-21 sequence to a 39 nt hairpin. We next added two extra GC pairs to mitigate 
end-fraying effects, yielding the 43 nt truncated pre-miR-21 oligoribonucleotide (2, Table 1). This construct was 
used as a starting point for the development of FRET-labelled oligoribonucleotides (5 and 7, Table 1, Fig. 1b,c) 
and corresponding donor-only oligoribonucleotides (6 and 8, Table 1) for our interbase-FRET assay. Because of 
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this oligoribonucleotide design, our assay has the potential to probe structural changes within pre-miRs using a 
highly sensitive fluorescence-based readout (Fig. 1b,c).
We envisioned that by replacing a pair of C residues in oligoribonucleotide 2 with the  tCO–tCnitro RNA 
FRET pair (Fig. 1d), we would be able to monitor changes in the FRET efficiency that arise from ligand bind-
ing (Fig. 1b,c). Furthermore, using sequences 5 and 7 in parallel (which report on different regions of the pre-
miR-21) also enables us to identify where the ligand binding takes place. Based on previous work regarding the 
 tCO–tCnitro inside the RNA  duplexes28, we anticipated that inserting this FRET pair would have a minimal effect 
on the pre-miR-21 structure. The corresponding 5′-biotinylated sequences (3 and 4, Table 1), enabling attach-
ment of the oligoribonucleotide to the streptavidin-coated surface, were prepared for immobilisation onto a 
streptavidin-coated SPR chip. Sequence 3 contains no donor or acceptor while sequence 4 contains the  tCO-tCnitro 
Figure 1.  Design of the interbase-FRET assay. (a) The full-length pre-miR-21 (1) with miR-21 sequence in 
red and Dicer cleavage sites marked by the black line. (b) Ligand binding to the hairpin loop region of FRET-
labelled pre-miR-21 construct (5, Table 1) causes a distance and/or orientation change between the fluorescent 
FRET donor (blue) and the non-fluorescent FRET acceptor (orange), thereby changing the FRET efficiency, and 
consequently, either an increase or a decrease in emission is observed. (c) Ligand binding to the stem FRET-
labelled pre-miR-21 construct (7, Table 1). (d) The chemical structures of the fluorescent FRET donor  tCO (blue) 
and the non-fluorescent FRET acceptor  tCnitro (orange).
Table 1.  Sequences of oligoribonucleotides used in this study. a Biot-C6 denotes 6-(5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentan-amido)hexyl phosphate. X denotes the fluorescent 
FRET donor  tCO and Y denotes the non-emissive FRET acceptor  tCnitro. Oligoribonucleotide 1 is the full-
length pre-miR-21. Oligoribonucleotide 2 is unmodified 43 nt pre-miR-21 hairpin used in ITC experiments. 
Oligoribonucleotide 3 is biotin-labelled unmodified 43 nt pre-miR-21 hairpin used in SPR experiments. 
Oligoribonucleotide 4 is biotin-labelled FRET pair modified 43 nt pre-miR-21 hairpin used in SPR. 
Oligoribonucleotides 5–8 are FRET pair or FRET donor modified 43 nt pre-miR-21 hairpins used in FRET 
experiments.
ID Oligoribonucleotide  sequencea
1 5ʹ-UGU CGG GUA GCU UAU CAG ACU GAU GUU GAC UGU UGA AUC UCA UGG CAA CAC CAG UCG AUG GGC UGU CUG ACA-3ʹ
2 5ʹ-CCG ACU GAU GUU GAC UGU UGA AUC UCA UGG CAA CAC CAG UCG G-3ʹ
3 5ʹ-biot-C6-CCG ACU GAU GUU GAC UGU UGA AUC UCA UGG CAA CAC CAG UCG G-3ʹ
4 5ʹ-biot-C6-CCG ACU GAU GUU GAX UGU UGA AUY UCA UGG CAA CAC CAG UCG G-3ʹ
5 5ʹ-CCG ACU GAU GUU GAC UGU UGA AUX UCA UGG YAA CAC CAG UCG G-3ʹ
6 5ʹ-CCG ACU GAU GUU GAC UGU UGA AUX UCA UGG CAA CAC CAG UCG G-3ʹ
7 5ʹ-CCG ACU GAU GUU GAX UGU UGA AUC UCA UGG CAA CAC YAG UCG G-3ʹ
8 5ʹ-CCG ACU GAU GUU GAX UGU UGA AUC UCA UGG CAA CAC CAG UCG G-3ʹ
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FRET pair (Table 1) to verify if the incorporation of our labelles has an impact on ligand binding readout when 
using the SPR technique.
ITC and SPR interaction reference measurements. ITC was used to explore experimental conditions 
for the aminoglycoside neomycin binding to unmodified truncated pre-miR-21 (2, Table 1), including optimiza-
tion of the buffer conditions. Ultimately, we employed a sodium cacodylate buffer (20 mM sodium cacodylate, 
80 mM NaCl, 100 mM total  Na+, pH 7.2) that was previously used in studies of aminoglycosides binding to the 
HIV-1 RNA dimerization initiation  site41. This buffer resulted in excellent reproducibility of the ITC binding 
isotherms and a dissociation constant (Kd) of 5.2 ± 0.8 µM for the interaction between pre-miR-21 2 and neo-
mycin (Fig. 2a,b).
To investigate whether the  tCO–tCnitro RNA FRET pair had any impact on the binding affinity between 
aminoglycosides and our FRET-labelled oligoribonucleotides, a comparative SPR measurement was performed 
using the biotinylated, FRET pair-containing pre-miR-21 (4, Table 1) and its FRET pair-free counterpart (3, 
Table 1). The Kd values of neomycin for sequences 3 and 4 were determined to be 3.9 ± 2.8 µM (Fig. 2c,d) and 
2.7 ± 1.7 µM (Table 2), respectively. These results agree well with the ITC data (Fig. 2a,b). The difference in affinity 
of neomycin for 3 and 4 was minor and within the experimental error of the SPR measurements. This strongly 
suggests that the FRET pair does not perturb the overall secondary structure of the pre-miR-21 construct nor 
the ligand–pre-miR interaction.
Dissociation constants of the pre‑miR‑21‑aminoglycoside interaction determined using 
SPR. To benchmark our interbase-FRET binding assay (vide infra), we investigated the binding affinities of a 
series of 12 aminoglycosides (Tables 2 and S2; see Figure S2 for structures) to pre-miR-21 3 and 4 using SPR. The 
obtained dissociation constants ranged from approximately 3 μM to 300 μM for both pre-miR-21 3 and 4, and 
these values were used to determine the SPR binding rank (Table 2). Because of the similar binding affinities for 
pre-miR-21 3 and 4, we concluded that the introduction of our FRET pair did not significantly alter the mode or 
strength of binding or the overall interaction between pre-miR and this type of ligand. Our results agree with a 
Figure 2.  Neomycin binding to pre-miR-21. (b) ITC data showing heat evolution upon titrating neomycin to 
oligoribonucleotide 2 (10 µM). (b) Integrated peak areas from panel (a) versus neomycin:2 molar ratio for the 
successive additions and the fitted curve (solid line, assuming a 1:1 binding) yielding a Kd of 5.2 ± 0.8 µM. (c) 
Neomycin binding to oligoribonucleotide 3 at 10 different concentrations using SPR, where the green marked 
region shows steady-state conditions from which Kd values are determined. (d) The fitted curve (solid line, 
assuming an equivalent affinity for all binding sites) from panel (c) yielding an average Kd of 3.9 ± 2.8 µM.
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previous study by Yan et al. in which a fluorescence polarization assay was used to identify neomycin, netilmicin, 
sisomicin, and tobramycin as particularly potent binders to pre-miR-2119. Notably, the aminoglycosides exhib-
ited a binding stoichiometry that varied between 4 and 5 depending on the aminoglycoside used, indicating that 
they bind non-specifically across pre-miR-21. Nearly identical binding stoichiometries were obtained for both 3 
and 4 (unlabeled vs. FRET-labeled, respectively) (Table S3).
Interbase‑FRET binding assay design. Our FRET-based assay for studying small-molecule binding to 
pre-miRs is based on evaluating the integrated emission of the FRET pair-labeled  (tCO and  tCnitro incorporated, 
donor–acceptor, DA) pre-miR sequence before and after addition of the ligand in relation to the same being 
performed for the FRET donor-containing  (tCO incorporated, donor only, D) pre-miR sequence (see Materials 
and Methods Eqs. 1–4). The ligand is added to the FRET-labeled pre-miR, and the change in emission for the 
DA strand relative to the corresponding D strand is measured. The FRET efficiency is calculated as the fraction 
of the integrated emission from the DA and D sequences (Eq. 1). The difference in FRET before and after ligand 
addition (ΔFRET, Eq. 2) is then normalized between the two different ligand binding experiments (vide infra) 
to obtain ΔFRETnorm (Eq. 3, Tables S4 and S5). The average ΔFRETnorm for the two different sets of FRET-labeled 
oligoribonucleotides (averaged ΔFRETnorm, Eq. 4) is used to rank the ligands (FRET rank), ranging from potent 
to less potent binders for the screened set of small molecules (Tables 2 and S6).
Aminoglycoside affinity rank for pre‑miR‑21 determined by interbase‑FRET assay. To obtain a 
significant change in FRET, the aminoglycosides (Table 2 and Figure S2) were added to sequences 5–8 (Table 1) 
at a concentration corresponding to a 90% degree of pre-miR-21 complexation. Higher degree of complexa-
tion would require non-feasible concentrations or volumes of the aminoglycoside stock solutions. The hairpin 
loop-labeled oligonucleotide (5, Table 1) showed a range of 2–5% with a 3% average increase in FRET efficiency 
(Figure S4), whereas the stem-labeled oligonucleotide (7, Figure S6) showed an average increase of 5% (except 
for hygromycin, which induced a decrease in FRET efficiency upon binding; Figure S6). For the donor-only con-
trol sequences (6 and 8, Table 1) small changes in FRET efficiency were observed (Figure S5 and S7), indicating 
that the local microenvironment of the donor changes upon the addition of aminoglycosides. Taken together, 
the results indicate that the aminoglycosides bind to the hairpin loop and to the stem parts of the FRET-labeled 
pre-miR constructs (5 and 7) and cause only small changes in the relative orientation/distance of the donor and 
acceptor. Furthermore, these results indicate that none of the aminoglycosides bind selectively to the hairpin 
loop or the stem parts of the labeled pre-miR constructs (5 and 7) but rather across the whole pre-miR. This is 
in agreement with the aminoglycoside:oligoribonucleotide binding ratio of 4–5:1 measured by SPR. It is also in 
line with work from the groups of Arenz and Maiti, showing that aminoglycoside antibiotics, such as kanamycin 
and streptomycin, generally inhibit Dicer-mediated miRNA processing by non-specific binding to the Dicer 
substrate, the pre-miR15,16.
The second set of ligand-binding experiments was designed to investigate whether our FRET-based assay 
could distinguish relative binding affinities of the aminoglycosides (Table 2, Figure S2). Furthermore, we wanted 
to investigate if ΔFRET for the aminoglycosides would correlate with the SPR affinity values.
Table 2.  SPR binding affinity for oligoribonucleotides 3 and 4, interbase-FRET binding affinity for 
oligoribonucleotides 5 and 7 and the respective rankings of all aminoglycosides. a Averaged ΔFRETnorm for the 
two FRET-labelled oligoribonucleotides (5 and 7) was calculated as an average of their ΔFRETnorm values. The 
latter ones were obtained by dividing the ΔFRET from adding aminoglycoside to reach the total concentration 
of 15 µM to 1 µM oligoribonucleotide by the ΔFRET from adding aminoglycoside to reach 90% degree of 
complexation of the same oligoribonucleotide (Eq. 3, Tables S4-S5). bSPR rank was determined from the 
average dissociation constant of oligoribonucleotides 3 and 4.
SPR Interbase-FRET
Aminoglycoside Kd [µM] of 3 Kd [µM] of 4 ΔFRET15µM of 5 ΔFRET15µM of 7
Averaged 
ΔFRETnorma SPR  Rankb FRET Rank
Neomycin 4 ± 3 3 ± 2 0.042 0.045 0.97 1 1
Sisomicin 4 ± 2 4 ± 2 0.023 0.041 0.68 2 3
Tobramycin 8 ± 4 8 ± 5 0.024 0.049 0.77 3 2
Amikacin 15 ± 4 14 ± 3 0.021 0.020 0.49 4 8
Gentamicin 16 ± 1 13 ± 3 0.011 0.040 0.64 5 6
Apramycin 22 ± 12 23 ± 12 0.017 0.037 0.67 6 4
Netilmicin 28 ± 35 27 ± 34 0.024 0.045 0.66 7 5
Kanamycin A 44 ± 18 45 ± 23 0.009 0.041 0.52 8 7
Ribostamycin 90 ± 73 78 ± 67 0.006 0.024 0.33 9 10
Geneticin 101 ± 44 94 ± 57 0.010 0.027 0.43 10 9
Streptomycin 134 ± 76 115 ± 80 0.004 0.008 0.13 11 11
Hygromycin 291 ± 91 291 ± 110 0.001 0.000 0.01 12 12
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Aminoglycosides were added to 1 µM FRET-labeled pre-miRs (5 and 7; Table 1) and their corresponding 
donor-only references (6 and 8; Table 1) at a total aminoglycoside concentration of 15 µM, chosen from SPR Kd 
as a middle-point between potent and non-potent binders (Table 2, Figure S8-S11). The data clearly show that 
high-affinity aminoglycosides such as neomycin (avg. SPR Kd = 3.3 µM, Table 2) caused a relatively large change 
in emission (avg. ΔFRET = 0.043 for 5 and 7, Table 2). By contrast, aminoglycosides with lower affinity such as 
streptomycin (avg. SPR Kd = 124 µM, Table 2) caused minimal changes in emission (avg. ΔFRET = 0.006 for 5 
and 7, Table 2, for further details see Table 2). Overall, this experiment enabled us to distinguish the most potent 
binders with ΔFRET of 0.02–0.04 from the less potent binders with ΔFRET of 0.000–0.02.
By comparing the averaged ΔFRETnorm values based on both types of FRET experiments (adding aminogly-
coside to reach a total concentration of 15 µM and adding aminoglycoside to reach a 90% degree of complexa-
tion; the latter representing the almost saturated binding event and hence a maximum change in FRET) and 
sorting them from high to low, the aminoglycosides were ranked based on FRET (Table 2, FRET Rank, Eq. 4). 
Overall, the FRET rank matched well with the SPR rank within a given class of ligand affinity (high, medium, 
and low), and the experimental errors of the two techniques were low. As in SPR, neomycin, sisomicin, and 
tobramycin were found to have the highest affinity for pre-miR-21 (avg. Kd < 10 µM, Table 2) using the FRET 
assay. Amikacin, gentamicin, apramycin, netilmicin, and kanamycin A all belong to the medium affinity group 
of pre-miR-21 ligands (avg. 15–45 µM, Table 2). A good correlation was observed when plotting the log Kd from 
SPR of 4 against the averaged ΔFRETnorm  (R2 = 0.82, Figure S4). Finally, ribostamycin, geneticin, streptomycin, 
and hygromycin were found to be low-affinity binders in SPR (avg. Kd > 84 µM) and in our FRET assay. Thus, 
our interbase-FRET binding assay discriminates between high-, medium- and low-affinity binders equally well 
as the established SPR technique.
Conclusion
In summary, we present a novel pre-miR binding assay based on interbase-FRET between a fluorescent  tCO donor 
and a non-fluorescent  tCnitro acceptor that incorporates into a pre-miR hairpin. Measuring the FRET efficiency 
changes enabled determination of the binding affinities between an onco-miR precursor (pre-miR-21, used here 
as a model pre-miR) and aminoglycoside antibiotics as small-molecule ligands. Initially, we used SPR to prove 
that the introduction of our FRET pair does not perturb the binding affinity. Importantly, changes in the FRET 
efficiency in our new established FRET-based assay correlated well with the Kd ranking of the aminoglycoside 
binding to pre-miR-21, as determined by the established SPR technique. We envisage that our assay will be useful 
for investigating ligand binding, including drug molecules and peptides, to various pre-miRs for the modulation 
of miR biogenesis and disease pathway modulation. Considering the low ligand and pre-miR amounts required 
and the sensitivity of our method, this assay should be compatible with high-throughput screening. We are 
currently investigating site-selective pre-miR binders using our novel interbase-FRET assay. Additionally, to 
increase its versatility, we have already expanded the RNA interbase-FRET methodology to include modifica-
tions of adenine  positions41.
Methods
Synthesis of RNA oligonucleotides. The pre-miR-21 and truncated pre-miR-21 oligoribonucleotide 
sequences used in this study are listed in Table 1. Sequences 3 and 5–8 were purchased from ATDBio Ltd, South-
ampton, UK and Eurogentec, Liège, Belgium, respectively. Oligoribonucleotides 5 and 7 contained a FRET pair, 
while 6 and 8 contained a FRET donor only. Oligoribonucleotides 2 and 4 were synthesized in-house; see the 
Supplementary Information for details on their synthesis and characterization.
General information on photophysical measurements and sample preparation. Sodium caco-
dylate buffer (20 mM sodium cacodylate, 80 mM NaCl, 100 mM total  Na+, pH 7.2) was used for all measure-
ments unless otherwise stated. Absorption spectra of the oligoribonucleotides were recorded between 200 and 
550 nm on a Cary 4000 or Cary 5000 (Varian Technologies) at a scan rate of 600 nm/min and spectral bandwidth 
of 2.0 nm. The absorption at 260 nm was used to calculate the oligoribonucleotide concentration, and the molar 
absorptivity at 260 nm was taken as the linear combination of the molar absorptivities of the individual bases 
at this wavelength, multiplied by 0.9 to account for the effect of base stacking. The values used for the molar 
absorptivity of each base at 260 nm were: ε(T) = 9300  M–1  cm–1, ε(C) = 7400  M–1  cm–1, ε(G) = 11,800  M–1  cm–1, 
ε(A) = 15,300   M–1   cm–1, ε(tCO) = 11,000   M–1   cm–1, and ε(tCnitro) = 9700   M–1   cm–1. All spectroscopic measure-
ments were carried out in a 0.3  cm pathlength quartz cuvette with a 45 µL chamber volume (Hellma). Pre-
miR annealing was achieved by heating the solution rapidly (approximately 5–10 °C/min) to 90 °C, holding for 
2.0 min, then cooling to 5.0 °C at approximately 1 °C/min. Aminoglycosides (Figure S2 in the Supporting Infor-
mation) were purchased from various chemical vendors. Stock solutions (10 mM) were prepared gravimetrically 
and further diluted to the desired concentrations.
Isothermal titration calorimetry (ITC) measurements. ITC was performed on a MicroCal iTC200 
from Malvern Panalytical. A 206 µL aliquot of 10 µM oligoribonucleotide was loaded into the sample cell of the 
ITC using a gastight syringe. Aminoglycoside (100–300 µM) was added to the ITC titration syringe, and the cell 
was kept at 25 °C. The initial delay time was set to 120 s and the stirring speed of the syringe to 750 rpm. In each 
addition, a volume of 2.0 μL was injected over the course of 2.0 s from the titration syringe into the cell. The total 
number of additions was 20, administered with 180 s intervals. The aminoglycoside–oligoribonucleotide bind-
ing data were corrected for the heat of ligand and oligoribonucleotide dilution by subtracting the average heat 
per injection of aminoglycoside to buffer and buffer to oligoribonucleotide, respectively. The Kd was determined 
using the Origin-based MicroCal iTC200 instrument software by non-linear curve fitting to a 1:1 binding model.
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Surface plasmon resonance (SPR) measurements. Biotinylated oligoribonucleotide was immo-
bilized on a streptavidin-coated biosensor chip (XanTec Bioanalytics GmbH). Capture levels were 300–500 
response units. Each aminoglycoside sample was injected over the surface in a 10 concentration–response series. 
Sensorgrams were fitted with a steady-state model (region shown in Fig. 2c) using the SPR module of the Gene-
data Screener software package to obtain the Kd values and assuming equivalent affinity for all binding sites. The 
immobilization step was repeated to ensure a fresh surface prior to each run. The stoichiometry was obtained by 
dividing the observed maximum response (Rmax) by the theoretical Rmax. The theoretical Rmax was obtained from 
the molecular weight ratio for each aminoglycoside vs. oligoribonucleotide multiplied by the total immobiliza-
tion level.
Fluorescence measurements and interbase‑FRET binding assay. Steady-state fluorescence emis-
sion spectra were recorded on a Spex Fluorolog 3 (JY Horiba) with excitation at 365 nm and the excitation slit 
width set to 1.5 nm. The initial concentration of the oligoribonucleotide sample was 1.0 µM in all measurements, 
and the initial sample volume was 60 µL. Emissions were recorded between 380 and 700 nm at a scan rate of 
600 nm  min–1, with the emission slit width set to 5.0 nm. All spectra were recorded in duplicate, which were 
averaged prior to further evaluation.
For experiments where the aminoglycoside was added to reach a 90% degree of FRET-labeled oligoribonu-
cleotide (5–8) complexation by the aminoglycoside, the dissociation constant obtained from SPR was used to 
calculate the required amount of aminoglycoside. SPR revealed a binding stoichiometry of 4–5:1 (aminoglycos
ide:oligoribonucleotide). However, owing to the simple binding dynamics observed (Fig. 2d), as well as nearly 
saturating the oligoribonucleotide with the aminoglycoside before measuring the emission spectrum, a 1:1 
binding model could be used.
Reaching a 90% degree of FRET-labeled oligoribonucleotide (5–8) complexation by the aminoglycoside was 
achieved by preparing 60 µL of the desired oligoribonucleotide at a concentration of 1 µM in a reduced volume 
quartz cuvette and adding 5 µL of varying concentrations of aminoglycoside solution (Table S7). Emission 
spectra of the FRET-labeled oligoribonucleotide (5 and 7) were recorded and compared before and after ligand 
addition. This procedure was then repeated for the corresponding oligoribonucleotide containing only the FRET 
donor (6 and 8, Table 1).
For experiments where the aminoglycoside was added to reach a final concentration of 15 µM in the cuvette, 
60 µL of 1 µM oligoribonucleotide was mixed with 1 µL of 915 µM aminoglycoside. An identical protocol to the 
one presented above was executed to obtain the emission spectra and calculate the FRET efficiency.
The averaged and normalized ΔFRET (averaged ΔFRETnorm) resulting in the ranking presented in Table 2 
was calculated by Eqs. (1–4), shown below.
The FRET efficiency (E) between the donor and acceptor within an oligoribonucleotide was calculated accord-
ing to Eq. (1):
where ID and IDA are the integrated (over wavelength) steady-state emission spectra for the donor only and 
donor–acceptor samples, respectively. The change in FRET efficiency (ΔFRET) was calculated according to 
Eq. (2):
where E0 and EL are the FRET efficiencies before and after addition of the ligand, respectively. The normalized 
change in FRET efficiency (ΔFRETnorm) was calculated according to Eq. (3):
where �FRET15µM is the change in FRET efficiency upon adding 15 µM ligand, and FRET90% is the change in 
FRET efficiency upon adding ligand at a concentration corresponding to a 90% degree of complexation (based on 
the Kd from SPR and assuming 1:1 binding). Finally, the AveragedFRETnorm was calculated according to Eq. (4):
where FRETnorm,5 and FRETnorm,7 are the normalized change in FRET efficiencies for oligoribonucleotides 
pairs 5 and 7, respectively.
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